Jupiter Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Hobe Sound, Florida.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Jupiter Acquisition Corp (0001817868) (Issuer)
4 - Jupiter Acquisition Corp (0001817868) (Issuer)
4 - Jupiter Acquisition Corp (0001817868) (Issuer)
4 - Jupiter Acquisition Corp (0001817868) (Issuer)
4 - Jupiter Acquisition Corp (0001817868) (Issuer)
15-12G - Jupiter Acquisition Corp (0001817868) (Filer)
8-K - Jupiter Acquisition Corp (0001817868) (Filer)
25-NSE - Jupiter Acquisition Corp (0001817868) (Subject)
8-K - Jupiter Acquisition Corp (0001817868) (Filer)
DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)
8-K - Jupiter Acquisition Corp (0001817868) (Filer)
DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)
DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)
DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)
DEFA14A - Jupiter Acquisition Corp (0001817868) (Filer)
Fastest customizable press release news feed in the world
VANCOUVER, BC, Dec. 19, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Business Combination Agreement, by and among the Company, Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter"), 1427702 B.C. Ltd. ("TopCo") and Filament Merger Sub LLC, dated as of July 18, 2023 (as amended by the First Amendment to the Business Combination Agreement, the "Business Combination Agreement"), with respect to a proposed business combination between Filament and Jupiter (the "Proposed Business Combination"), has been terminated by the parties by mutual agreement.
Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter") today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the "Business Combination Agreement"). The special meeting of stockholders of Jupiter scheduled to reconvene on Thursday, December 28, 2023, at 12:00 p.m. Eastern Time, at which stockholders of Jupiter were to be asked to vote to approve the Business Combination Agreement and the business combination contemplated thereby, among other related matters, has been cancelled. Jupiter will redeem all of the outstanding shares of its Class A common stock i
VANCOUVER, BC, Dec. 18, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of its securityholders held this Monday, December 18, 2023 at 9:30 a.m. (Vancouver time) (the "Special Meeting") to approve, among other things, the Company's proposed arrangement (the "Arrangement") under Part 9, Division 5 of the Business Corporations Act (British Columbia) was terminated. At the Special Meeting, the Arrangement Resolution attached to the management information circular of Filament dated November 7, 2023 (the "Circular") was not presented to the se
Hobe Sound, FL, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter") today announced that it intends to reconvene and then adjourn, without conducting any business, the special meeting of stockholders of Jupiter (the "Business Combination Special Meeting") scheduled to reconvene on Tuesday, December 12, 2023, at 12:00 p.m. Eastern Time, until Monday, December 18, 2023, at 12:00 p.m. Eastern Time, as a completely virtual meeting conducted via live webcast, which will be available at https://www.cstproxy.com/jupiteracquisitioncorp/sm2023. At the Business Combination Special Meeting, once further reconvened, stockholders of Jupiter will be asked to vote
VANCOUVER, BC, Dec. 11, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. (Vancouver time) (the "Special Meeting") to approve, among other things, the Company's proposed arrangement (the "Arrangement") under Part 9, Division 5 of the Business Corporations Act (British Columbia) (the "Act") has been adjourned. The Special Meeting has been adjourned in acc
VANCOUVER, BC, Dec. 6, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, is pleased to announce that, further to its press release dated November 23, 2023, the Company has entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") with Helena Global Investment Opportunities 1 Ltd. (the "Note Investor"), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor ("Helena") and 1427702 B.C. Ltd. ("TopCo"), providing for up to USD$14.4 million in funding through the issuance of senior secured convertible notes (the "Notes" an
Hobe Sound, FL, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter") today announced that it intends to convene and then adjourn, without conducting any business, the special meeting of stockholders of Jupiter (the "special meeting") scheduled to occur on Tuesday, December 5, 2023, at 12:00 p.m. Eastern Time, until Tuesday, December 12, 2023, at 12:00 p.m. Eastern Time, as a completely virtual meeting conducted via live webcast, which will be available at https://www.cstproxy.com/jupiteracquisitioncorp/sm2023. At the special meeting, once reconvened, stockholders of Jupiter will be asked to vote on the proposals described in the definitive proxy state
VANCOUVER, BC, Aug. 15, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation ((JAQC) ("Jupiter"), a special purpose acquisition company ("SPAC"), today announced the filing of a registration statement by 1427702 B.C. Ltd. ("TopCo") on Form F-4 (the "Registration Statement"), which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission ("SEC") in connection with the proposed Business Combination announced July 19, 2023.
Business combination ascribes Filament US$176 million in equity value representing US$0.85 per Filament share and reflects a pro forma enterprise valuation of approximately US$210 million; combined company to be listed on Nasdaq Transaction expected to accelerate the progression of Filament's botanical psychedelic drug development platform and is anticipated to close in fourth quarter 2023 VANCOUVER, BC and HOBE SOUND, Fla., July 19, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter"), a special purpose acquisition compa
This live feed shows all institutional transactions in real time.
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13D/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)
SC 13G/A - Jupiter Acquisition Corp (0001817868) (Subject)